Moxonidine is a new-generation centrally acting antihypertensive drug, which is approved for the treatment of mild to moderate essential hypertension. moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. Reference standards of Moxonidine API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Moxonidine impurity A (Y0000222) [catalogue_number] => PA EPY0000222 [category_ids] => ,150, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => moxonidine-impurity-a-y0000222-paepy0000222 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA EPY0000222
CAS :
Molecular Formula : NA
Molecular Weight : NA
stdClass Object ( [pname] => Moxonidine (Y0000226) [catalogue_number] => PA EPY0000226 [category_ids] => ,150, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => moxonidine-y0000226-paepy0000226 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA EPY0000226
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....